Merck is in talks to acquire Revolution Medicines, a company specializing in cancer treatments, specifically a new pancreatic cancer therapy. This potential acquisition could expand Merck's portfolio in oncology and boost its presence in the cancer treatment market. The deal's impact on Merck's stock price remains uncertain.